-
Leveraging Hot Melt Extrusion for Solubility and Continuous Manufacturing
Hot melt extrusion (HME) technology leads to enhanced solubility.
PAP-Q2-18-CL-007 -
Inside Mergers & Acquisitions
Innovation and efficiency are both key to successful drug development and commercialization.
PAP-Q2-18-CL-001 -
Changes in the Biopharma Industry: from Minor to Major Evolution
The biopharmaceutical industry continues to grow rapidly. Targeted biologics are helping treat previously untreatable diseases.
PAP-Q2-18-NI-002 -
Supporting Patient-Centric Clinical Trials from Point-of-Origin through the Last Mile
The clinical trial paradigm has shifted.
PAP-Q2-18-CL-002 -
Taking Middle-Market CROs and CDMOs to the Next Level
Smaller outsourcing organizations often need assistance moving to the next level.
PAP-Q2-18-CL-003 -
Addressing Development Challenges for Complex Biologic Drug Candidates
Biotherapeutics identified as potential drug candidates are increasingly complex.
PAP-Q2-18-CL-004 -
Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence
Next-generation viral vector and gene therapy manufacturing facilities must be flexible.
PAP-Q2-18-CL-005 -
Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network
As biologic drugs become more complex and sophisticated, biopharmaceutical companies increasingly need the support of contract development and manufacturing organizations (CDMOs) with advanced capabilities and technology platforms that are consistently implemented across scales and geographies.
PAP-Q2-18-CL-006 -
Building a Biologics Business from the Ground Up
Building a biologics business from the ground up provides tremendous flexibility but requires the right business strategy.
PAP-Q2-18-CL-008 -
Using a Risk-Based Approach to Manufacturing in a Multi-Product Facility
Manufacturing in multi-product facilities affords numerous advantages- and challenges.
PAP-Q2-18-CL-009 -
State-of-the-Art Biologics Manufacturing in an Unexpected Location
Biotechpharma UAB, located in Vilnius, is exporting biologic drug substances worldwide.
PAP-Q2-18-CL-010 -
Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing
Viral vector manufacturers involved in all stages of clinical-trial-material and commercial product production rely on single-use (SU) technologies.
PAP-Q2-18-CL-011 -
Modern OSD Facility Design Considerations for Operational Efficiency and Regulatory Compliance
Oral solid dosage (OSD) remains the preferred dosage delivery form for the formulation of many of today’s drug products.
PAP-Q2-18-CL-012 -
Strengthening the Outsource Service Offering through Integration
Controlling costs and increasing efficiencies are two fundamental drivers for outsourcing of pharmaceutical manufacturing.
PAP-Q2-18-CL-013 -
Corporate Social Responsibility as a Driver for Improved Sustainability
The pharmaceutical industry must respond to growing expectations regarding the environmental impact of medicinal products and manufacturing.
PAP-Q2-18-CL-014 -
Challenges for Next-Generation Biological Therapeutics Discovery and Development
In the last three and half decades, the focus of drug discovery and development has gradually shifted to large, complex molecular entities — therapeutic biologics.
PAP-Q2-18-FA-001 -
Thinking a Generation Ahead: Biologics-Based Therapy
Whether dealing with stem cells, CRISPR Cas-9 technology or antibody-drug conjugates, there is no shortage of innovation - the challenge is scaling up.
PAP-Q2-18-FA-002 -
Finishing Touches – The Future of Fill-Finish and Pharma Packaging
Fill-finish has remained relatively stable in spite of myriad developments in the industry over the last decade.
PAP-Q2-18-FA-003 -
Maximizing ROI through Equipment Liquidation
Cost pressures are significant drivers for pharmaceutical manufacturers seeking to eliminate redundancies and increase productivity and efficiency.
PAP-Q2-18-CL-015 -
Experience Meets Flexibility
Advances in rapid synthesis technologies are leading to the preparation of new classes of compounds with attractive therapeutic properties.
PAP-Q2-18-CL-016 -
Scientific Expertise Facilitates Oral Peptide Product Development and Manufacturing
Most often developed as injectable formulations, a few “oral peptide” drugs have been approved in recent years.
PAP-Q2-18-CL-017 -
Achieving Controlled Nucleation During Aseptic Lyophilization
Controlled nucleation is essential for obtaining high-quality lyophilized products with intra- and inter-batch consistency.
PAP-Q2-18-CL-018 -
BioPharma CDMO Success Requires Technical Leadership and Problem-Solving Capabilities
Since their introduction, biologic drugs have shown great potential to treat diseases not possible to remedy with traditional small-molecule drugs.
PAP-Q2-18-CL-019 -
Providing Flexible Capabilities to Meet Market Demand for Sterile Fill-Finish Services
The fill-finish step in the manufacturing of drugs is the last step completed before a product is packaged and delivered to the patient.
PAP-Q2-18-CL-020 -
DOPING – Famous Cases, Substances and Values in Sports
Doping remains a constant threat to the ethics and values in professional sports, as well as on the amateur level.
PAP-Q2-18-NI-003
-
Dissolving Boundaries in Worldwide Clinical Trial Logistics for Biological Samples and New Therapies
Ariette van Strien, Chief Commercial Officer and Daniel Bell, Vice President, Regulatory Compliance & Technical Affairs at Marken, discuss clinical trial logistics without boundaries.
-
Cultivating a Proactive Quality Culture
Phillippe Dartiguelongue, Industry Quality Director at Servier CDMO explains how emphasis on quality mitigates patient risk.
-
Five Critical Considerations for Pharmaceutical M&A
Merger and acquisition (M&A) activity is deeply embedded into the culture of the pharmaceutical industry, here's what to keep in mind.
-
Supporting the Pharma Industry Small Business Growth Engine
Syed T. Husain, Chief Commercial Officer and Catherine Hanley, Head of Marketing & Corporate Communications at Alcami explain how CDMOs can help bolster smaller players in pharma.
-
Antibody-Drug Conjugate: Do We Understand The Capital Investment In Our Staff?
Industry experts weigh in on our Roundtable question.
-
Designing Effective Drug Formulations: Keys to Successful Proof of Concept Services
Ed Scholtz, Ph.D., Vice President of R&D for UPM Pharmaceuticals explains the company's approach to formulations.
-
AMPAC Fine Chemicals to Be Acquired By SK Holdings
This acquisition is the largest M&A transaction announced in the Korean pharmaceutical industry.
-
New Antibiotic to be Tested against Potential Bioweapons
US government agencies funding investigation of Spero Therapeutics’ SPR994 antibiotic.
-
FDA Committee Gives Nod to New Treatment for Plasmodium Vivax Malaria
Drug developed by GSK in collaboration with Medicines for Malaria Venture if approved would be first single-dose treatment for prevention of relapse.
-
Upsher-Smith Launches Vigabatrin for Oral Solution Under The Brand Name Vigadrone™
Vigadrone™ (vigabatrin) for Oral Solution, 500 mg is a fully substitutable, AA-rated generic version of Sabril®(vigabatrin) powder for oral solution.
-
Achieving Controlled Nucleation During Aseptic Lyophilization
Controlled nucleation is essential for obtaining high-quality lyophilized products with intra- and inter-batch consistency, says Robert Darrington, VP, Technical Marketing, SP Industries, Inc.
-
Keys to Cultural Integration
That’s Nice sat down with Catherine Hanley, Alcami’s Director of Marketing, to find out how to successfully integrate after a merger.
-
Leveraging Hot Melt Extrusion for Solubility and Continuous Manufacturing
Hot melt extrusion (HME) technology has become a key solution to adding absorption for enhanced solubility, says Tony Listro, Vice President, Technical Business Development at Foster Delivery Science.
-
Becoming Bioavailable
Poorly soluble molecules in the pipeline can have a negative effect on your active pharmaceutical ingredient (API).
-
Making Real-Time Process Analytical Technology In Biomanufacturing A Reality
Clint Pepper, Ph.D., Director of MAST Technology at Capsugel, explains the Modular Automated Sampling Technology platform.
-
What are the Greatest Challenges Drug Manufacturers Face When Working to Meet the New Requirements for Excipient Supply Chain Security?
Industry experts weigh in on our Roundtable question.
-
AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax
The US Food and Drug Administration (FDA) has granted venetoclax two Breakthrough Therapy Designations (BTDs) in AML, which are designed to expedite the development and review of medicines that are intended to treat a serious condition.
-
New Treatment for Excessive Sweating Gets FDA Approval
Demira’s awareness campaign for Qbrexa is drawing significant interest.
-
Abbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves
The next-generation MitraClip system provides cardiologists with advanced steering, navigation, and positioning capabilities for the clip, making it easier to use in difficult anatomies.
-
Women’s Health Company to Expand
Scottish company DYSUS Medical raises $25 million from Lundbeckfonden Ventures.
THE ROAD TO BIO: THE EXTENDED STORY
View AllRoad To BIO: Coming Soon To Your Screen Q4 2018
The Road to BIO in Review
The Road To BIO: Day 12 California
The Road To BIO: Day 11 Arizona /// California
The Road To BIO: Day 10 Texas /// Arizona
The Road To BIO: Day 9 Texas
The Road To BIO: Day 8 Texas
The Road To BIO: Day 7 Mississippi /// Texas
The Road To BIO: Day 6 Georgia /// Mississippi
The Road To BIO: Day 5 South Carolina /// Georgia
The Road To BIO: Day 4 Tennessee /// South Carolina
The Road To BIO: Day 3 Pennsylvania /// Tennessee
The Road To BIO: Day 2 New York /// Pennsylvania
The full story of this epic journey can be experienced as an audiobook. Listen to the story behind the story – the characters, the challenges, and all 12 days of the Road To BIO.
Nice Insight Awareness/Perception Scorecard
Research. Compare. Contact. Find the Ideal Partner.
Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.
- Search by company type, region, market segment and services.
- Select up to 5 companies to compare.
- View CA & CP performance scores against industry benchmark ratings.
Latest
View All LatestFDA Committee Gives Nod to New Treatment for Plasmodium Vivax Malaria
Jul 17, 2018 2:16:02 PM PAO-M07-18-NI-010
TOPICS
View All TopicsPRESS RELEASES
View All-
Leiters and Avanos Medical Announce Preferred Provider Agreement
Jul 17, 2018 5:00:00 AM -
Upsher-Smith Launches Vigabatrin For Oral Solution Under The Brand Name Vigadrone™
Jul 17, 2018 5:00:00 AM -
AMPAC Fine Chemicals To Be Acquired By SK Holdings
Jul 17, 2018 5:00:00 AM -
FDA approves the first drug with an indication for treatment of smallpox
Jul 16, 2018 7:00:00 AM -
Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis
Jul 16, 2018 7:00:00 AM
Nice Insight Industry Benchmark Reports 2017
Download Sample Report
